Affiliation: University of North Carolina
- Upper gastrointestinal tract endoscopy in inflammatory bowel diseaseKim L Isaacs
Division of Digestive Diseases and Nutrition, University of North Carolina School of Medicine, CB 7080, Room 3034B, Old Clinic Building, Chapel Hill, NC 27599 7080, USA
Gastrointest Endosc Clin N Am 12:451-62, vii. 2002..Upper gastrointestinal endoscopy may allow for therapeutic intervention in terms of bleeding and stricturing disease...
- Fistula treatment: The unresolved challengeStephan R Vavricka
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
Dig Dis 28:556-64. 2010..The unresolved challenges in fistula treatment warrant randomized controlled trials for existing and future treatment strategies as well as a better classification system to compare available studies...
- How rapidly should remission be achieved?Kim L Isaacs
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599 7032, USA
Dig Dis 28:548-55. 2010..In this presentation induction of clinical remission and mucosal healing in Crohn's disease and ulcerative colitis will be discussed. The impact of early remission on disease course will also be reviewed...
- Role of probiotic therapy in IBDKim Isaacs
University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, NC 27599 7032, USA
Inflamm Bowel Dis 14:1597-605. 2008..This review examines the data of all fully published articles currently available for the role of probiotics in the treatment of IBD...
- Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot studyKim L Isaacs
University of North Carolina, Chapel Hill, North Carolina 27599 7032, USA
Inflamm Bowel Dis 13:1250-5. 2007..The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown...
- Treatment of inflammatory bowel disease with antibioticsKim L Isaacs
Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, 27599 7080, USA
Gastroenterol Clin North Am 33:335-45, x. 2004..This article summarizes published studies of antibiotics in IBD patients and reviews available data for the use of antibiotic therapy in Crohn's disease and ulcerative colitis...
- Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experienceMillie D Long
University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, North Carolina 27599 7080, USA
Inflamm Bowel Dis 17:1855-62. 2011..Capsule endoscopy (CE) is performed to assess inflammatory bowel disease (IBD). We aimed to define the results of CE in subtypes of IBD and to determine whether CE results in management changes...
- A randomized, controlled, double-blind trial of air insufflation versus carbon dioxide insufflation during ERCPEvan S Dellon
Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7080, USA
Gastrointest Endosc 72:68-77. 2010..Carbon dioxide (CO(2)) insufflation decreases postprocedure abdominal discomfort and distension after colonoscopy, but there have been few published studies on its use in ERCP...
- Efficacy of methotrexate in ulcerative colitis: failure or promiseHans H Herfarth
Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Inflamm Bowel Dis 16:1421-30. 2010....
- Crohn's disease of the esophagusKim L Isaacs
Kim L Isaacs, MD, PhD Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, CB 7032, Room 7200 MBRB, Chapel Hill, NC 27599 7032, USA
Curr Treat Options Gastroenterol 10:61-70. 2007..Surgery may be required for severe, refractory symptoms, but it has a high morbidity in this population...
- State of the art: IBD therapy and clinical trials in IBDKim L Isaacs
University of North Carolina, Chapel Hill, North Carolina, USA
Inflamm Bowel Dis 11:S3-12. 2005..The number of products under development and continued investigations into the pathogenesis of IBD emphasize the need to expand clinical research efforts in IBD...
- NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African AmericansThemistocles Dassopoulos
Gastroenterology Division, Department of Medicine, The Harvey M and Lyn P Meyerhoff Inflammatory Bowel Disease Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Am J Gastroenterol 105:378-86. 2010..NOD2 mutations and anti-Saccharomyces cerevisiae antibodies (ASCAs) are established risk factors of Crohn's disease (CD) in whites but have not been assessed in African-American (AA) adults with CD...
- Design issues and outcomes in IBD clinical trialsBruce E Sands
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Inflamm Bowel Dis 11:S22-8. 2005..Careful subject selection, standardization of disease activity indices, and precise outcome measurement are the keys to continued improvement of the inflammatory bowel disease research process...
- Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trialWilliam J Sandborn
Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905, USA
Gastroenterology 125:380-8. 2003..This study determined the effectiveness of tacrolimus for the treatment of Crohn's disease fistulas...
- A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitisStefan Schreiber
Department of General Internal Medicine, Christian Albrechts University, Schittenhelmstrasse 12, Kiel Schleswig Holstein 24105, Germany
Gastroenterology 132:76-86. 2007..Tetomilast (OPC-6535), a novel thiazole compound, inhibits phosphodiesterase-4 and proinflammatory functions of leukocytes including superoxide production and cytokine release...